- Home
- JCSE vs APLM Comparison
JCSE vs APLM Comparison
Compare JCSE & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCSE
- APLM
- Stock Information
- Founded
- JCSE 1999
- APLM 2016
- Country
- JCSE Singapore
- APLM United States
- Employees
- JCSE N/A
- APLM N/A
- Industry
- JCSE Miscellaneous manufacturing industries
- APLM Blank Checks
- Sector
- JCSE Consumer Discretionary
- APLM Finance
- Exchange
- JCSE Nasdaq
- APLM Nasdaq
- Market Cap
- JCSE 6.3M
- APLM 6.9M
- IPO Year
- JCSE 2022
- APLM N/A
- Fundamental
- Price
- JCSE $1.14
- APLM $6.41
- Analyst Decision
- JCSE
- APLM
- Analyst Count
- JCSE 0
- APLM 0
- Target Price
- JCSE N/A
- APLM N/A
- AVG Volume (30 Days)
- JCSE 9.1K
- APLM 4.4K
- Earning Date
- JCSE 05-15-2025
- APLM 08-13-2025
- Dividend Yield
- JCSE 8.11%
- APLM N/A
- EPS Growth
- JCSE N/A
- APLM N/A
- EPS
- JCSE 0.00
- APLM N/A
- Revenue
- JCSE $14,126,397.00
- APLM $198,000.00
- Revenue This Year
- JCSE N/A
- APLM $415.15
- Revenue Next Year
- JCSE N/A
- APLM N/A
- P/E Ratio
- JCSE $248.85
- APLM N/A
- Revenue Growth
- JCSE 6.92
- APLM N/A
- 52 Week Low
- JCSE $0.70
- APLM $4.47
- 52 Week High
- JCSE $2.39
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- JCSE 50.65
- APLM 51.61
- Support Level
- JCSE $1.08
- APLM $5.34
- Resistance Level
- JCSE $1.14
- APLM $6.70
- Average True Range (ATR)
- JCSE 0.05
- APLM 0.52
- MACD
- JCSE -0.00
- APLM -0.03
- Stochastic Oscillator
- JCSE 37.65
- APLM 67.65
About JCSE JE Cleantech Holdings Limited
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The product lives of its cleaning systems and other equipment range from two to ten years. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. It derives a majority of its revenue from Singapore.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.